Niagen Bioscience Q2 sales fall 4% to $29.8 million; net income drops to $1.0 million
Niagen Bioscience reported second-quarter 2026 net sales of $29.8 million, down from $31.1 million a year earlier, and net income of $1.0 million, down from $3.6 million. The company expects operating expenses to rise in 2026 as it invests in pharmaceutical, telehealth and skincare initiatives, and it expects its ingredient business to be lower than last year.
Key points
- Q2 2026 net sales were $29.8 million versus $31.1 million in Q2 2025; Tru Niagen sales were $24.2 million.
- Net income was $1.0 million, or $0.01 per diluted share, versus $3.6 million, or $0.04, a year earlier; adjusted EBITDA was $3.0 million versus $5.0 million.
- For 2026, e-commerce is expected to grow 10% to 15%, while the ingredient business is expected to be lower than the prior year and operating expenses are expected to increase.
- NB4168, a lead investigational therapeutic, received FDA Rare Pediatric Disease designation for Ataxia-Telangiectasia; preclinical studies with Evotec are expected to begin in Q3 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.